HC Wainwright & Co. Reiterates Buy on ProPhase Labs, Maintains $15 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates ProPhase Labs (NASDAQ:PRPH) with a Buy and maintains $15 price target.
ProPhase Labs Announces Plans To Initiate Clinical Trial Of Equivir, Goal To Launch Commercially In Q4 2023
ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase"), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that its wholly-owned subsidiary, ProPhase BioPharma, Inc. (PBIO), is
ProPhase Labs Esophageal Cancer Early Detection Test (BE-smart) Featured in Peer-Reviewed Article in the International Journal of Molecular Science
To date, the BE-Smart test has been tested on over 200 human samples by mProbe Inc, a precision health and medicine company utilizing clinical proteomics in the oncology space, and has shown greater
HC Wainwright & Co. Reiterates Buy on ProPhase Labs, Maintains $15 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates ProPhase Labs (NASDAQ:PRPH) with a Buy and maintains $15 price target.
Prophase Labs’ Prophase Labs Will Acquiring New Equipment Which Is Expected To Double Its Current Capacity For Pouch Packaging By Q2 Of 2023. Pharmaloz Is Also Planning For Expansion Of Its Lozenge Manufacturing Business
Altogether, these expansion initiatives are expected to lead to a 200% increase in capacity for 2024 as compared to 2022. It is currently expected that the Pharmaloz expansion will be funded entirely from
HC Wainwright & Co. Reiterates Buy on ProPhase Labs, Maintains $15 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates ProPhase Labs (NASDAQ:PRPH) with a Buy and maintains $15 price target.
5 Value Stocks In The Healthcare Sector
What are Value Stocks? A value stock traditionally has a lower price when compared to stock prices of…
5 Value Stocks In The Healthcare Sector
The Meaning Behind Value Stocks A value stock traditionally has a lower price when compared to stock prices…
HC Wainwright & Co. Maintains Buy on ProPhase Labs, Raises Price Target to $15
HC Wainwright & Co. analyst Yi Chen maintains ProPhase Labs (NASDAQ:PRPH) with a Buy and raises the price target from $14 to $15.
Why Olaplex Shares Dipped Around 57%; Here Are 75 Biggest Movers From Yesterday
Gainers
Amprius Technologies, Inc. (NYSE: AMPX) jumped 77.3% to settle at $11.01 on Wednesday after the company announced it was awarded a $50 million cost-sharing grant from the U.S. Department of Energy's Office of Manufacturing and Energy Supply Chains.